ArticleBMC microbiology2026
Pf41 serological profiling reveals potential malaria exposure in low transmission setting in the Menoreh Hills, Central Java, Indonesia.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPf41 serological profiling may serve as an additional sero-epidemiological tool to characterize past malaria exposure, particularly in low-transmission settings where routine parasitological methods have limited capacity to detect historical exposure. In the Menoreh Hills, Central Java, where malaria transmission is low and unstable, such profiling can reveal exposure history that are not captured by conventional parasitological methods. This study evaluates the utility of Pf41 antibody responses as an exposure marker in a low-transmission context, with the Menoreh Hills serving as an epidemiologically relevant field site.
methodsA cross-sectional seroepidemiological study was conducted from January to June 2025 in four malaria-endemic villages: Sedayu, Kemejing, Kembaran, and Wadas. Serum samples from 120 individuals in malaria endemic villages and 24 healthy non-exposed controls were analyzed for anti-Pf41 IgG antibodies using a protein microarray. Demographic and behavioral data were collected through structured questionnaires, and statistical analyses were performed to assess differences in antibody responses and their associations with demographic and exposure-related factors.
resultsThe results revealed a high overall Pf41 seropositivity rate of 71% (85/120) among individuals in malaria endemic villages, with marked heterogeneity across villages: Kembaran 93%, Sedayu 83%, Wadas 60%, and Kemejing 47%. Mean standardized MFI was significantly higher in all exposed groups compared to controls (p < 0.001). At the individual level, Pf41 antibody responses were significantly associated with selected behavioral factors in a site-specific manner. In Sedayu, behavioral factors showed a site-specific pattern, with frequent mosquito bites during outdoor activities at night being associated with higher Pf41 antibody levels. In Kemejing, higher antibody levels were observed among individuals who fed livestock at night. In the pooled analysis across all study sites, nighttime livestock feeding and the use of repellent was significantly associated with increased Pf41 antibody levels.
conclusionsThese findings indicate that serological evidence of past malaria exposure remains detectable in the Menoreh Hills despite a decline in reported clinical cases, with antibody responses varying across villages and reflecting differences in behavioral risk profiles. The integration of Pf41 serology into malaria surveillance systems could complement existing approaches by contributing to the identification of populations or areas with serological evidence of prior malaria exposure in low-transmission settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.